Publicaciones en las que colabora con Pilar Llamas Sillero (31)

2024

  1. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152

  2. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  3. External validation of the PE-SARD risk score for predicting early bleeding in acute pulmonary embolism in the RIETE Registry

    Thrombosis Research, Vol. 235, pp. 22-31

  4. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  5. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

  6. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

  7. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

    Blood Advances, Vol. 8, Núm. 18, pp. 4950-4959

2022

  1. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4

2021

  1. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989

  2. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

    European Respiratory Journal, Vol. 58, Núm. 1

  3. Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19

    Seminars in Thrombosis and Hemostasis, Vol. 47, Núm. 4, pp. 351-361

  4. Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation

    Research and Practice in Thrombosis and Haemostasis, Vol. 5, Núm. 1, pp. 168-178

  5. Timing and characteristics of venous thromboembolism after noncancer surgery

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 9, Núm. 4, pp. 859-867.e2

  6. Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study

    Thrombosis Research

2020

  1. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism (Internal and Emergency Medicine, (2019), 14, 7, (1101-1112), 10.1007/s11739-019-02077-5)

    Internal and Emergency Medicine

  2. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry

    Journal of Internal Medicine, Vol. 287, Núm. 1, pp. 32-41

  3. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

    Thrombosis Update, Vol. 1

  4. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 8, Núm. 3, pp. 353-359.e1

2019

  1. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

  2. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism (Internal and Emergency Medicine, (2019), 14, 7, (1101-1112), 10.1007/s11739-019-02077-5)

    Internal and Emergency Medicine